Cargando…

A multicenter, open‐label, single‐arm study of anamorelin (ONO‐7643) in patients with cancer cachexia and low body mass index

BACKGROUND: Cancer cachexia is a syndrome characterized by anorexia and decreased body weight. This study evaluated the efficacy and safety of anamorelin, an orally active, selective ghrelin receptor agonist, in patients with cancer cachexia and a low body mass index (BMI). METHODS: This multicenter...

Descripción completa

Detalles Bibliográficos
Autores principales:	Naito, Tateaki, Uchino, Junji, Kojima, Toru, Matano, Yutaka, Minato, Koichi, Tanaka, Kentaro, Mizukami, Takuro, Atagi, Shinji, Higashiguchi, Takashi, Muro, Kei, Takayama, Koichi, Furuse, Junji, Morishima, Eiichiro, Takiguchi, Toru, Tamura, Kazuo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303784/ https://www.ncbi.nlm.nih.gov/pubmed/35195274 http://dx.doi.org/10.1002/cncr.34154

Ejemplares similares

A multicenter, open‐label, single‐arm study of anamorelin (ONO‐7643) in advanced gastrointestinal cancer patients with cancer cachexia
por: Hamauchi, Satoshi, et al.
Publicado: (2019)

Anamorelin (ONO‐7643) for the treatment of patients with non–small cell lung cancer and cachexia: Results from a randomized, double‐blind, placebo‐controlled, multicenter study of Japanese patients (ONO‐7643‐04)
por: Katakami, Nobuyuki, et al.
Publicado: (2017)

Anamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: results of a randomized phase 2 trial
por: Takayama, Koichi, et al.
Publicado: (2016)

Efficacy and safety of anamorelin in patients with cancer cachexia: Post‐hoc subgroup analyses of a placebo‐controlled study
por: Takayama, Koichi, et al.
Publicado: (2022)

Anamorelin HCl (ONO-7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia-cachexia syndrome: preclinical profile
por: Pietra, Claudio, et al.
Publicado: (2014)

Effect of ghrelin and anamorelin (ONO-7643), a selective ghrelin receptor agonist, on tumor growth in a lung cancer mouse xenograft model
por: Northrup, R., et al.
Publicado: (2013)

Combination therapy with anamorelin and a myostatin inhibitor is advantageous for cancer cachexia in a mouse model
por: Hanada, Kako, et al.
Publicado: (2022)

Factors associated with early discontinuation of anamorelin in patients with cancer-associated cachexia
por: Tsukiyama, Ikuto, et al.
Publicado: (2023)

Evidence for partial pharmaceutical reversal of the cancer anorexia–cachexia syndrome: the case of anamorelin
por: Anker, Stefan D, et al.
Publicado: (2015)

Three‐year follow‐up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non‐small cell lung cancer: Pooled analysis of ONO‐4538‐05 and ONO‐4538‐06 studies
por: Horinouchi, Hidehito, et al.
Publicado: (2019)

Five-year follow-up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non-small cell lung cancer: pooled analysis of the ONO-4538-05 and ONO-4538-06 studies
por: Saka, Hideo, et al.
Publicado: (2020)

Anamorelin hydrochloride in the treatment of cancer anorexia–cachexia syndrome: design, development, and potential place in therapy
por: Graf, Solomon A, et al.
Publicado: (2017)

Oncology Update: Anamorelin
por: Prommer, Eric
Publicado: (2017)

Impact of the Extent of Weight Loss before Administration on the Efficacy of Anamorelin in Advanced Pancreatic Cancer Patients with Cachexia
por: Takeda, Tsuyoshi, et al.
Publicado: (2022)

Predictors of efficacy of anamorelin in patients with non‑small cell lung cancer and cachexia: A retrospective study
por: Ishioka, Yoshiko, et al.
Publicado: (2023)

The efficacy and safety of anamorelin for patients with cancer-related anorexia/cachexia syndrome: a systematic review and meta-analysis
por: Taniguchi, Jumpei, et al.
Publicado: (2023)

Quality of life and survival survey of cancer cachexia in advanced non-small cell lung cancer patients—Japan nutrition and QOL survey in patients with advanced non-small cell lung cancer study
por: Takayama, Koichi, et al.
Publicado: (2016)

A case of squamous cell lung cancer treated with anamorelin in combination with a multidisciplinary collaborative approach for treating cancer cachexia
por: Oshima, Yuri, et al.
Publicado: (2022)

Refractory Monomorphic Ventricular Tachycardia Induced by Anamorelin
por: Sakagami, Hiroaki, et al.
Publicado: (2022)

ROMANA 3: a phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia
por: Currow, D., et al.
Publicado: (2017)

Innovative therapeutic strategy using prostaglandin I(2) agonist (ONO1301) combined with nano drug delivery system for pulmonary arterial hypertension
por: Kanaya, Tomomitsu, et al.
Publicado: (2021)

Evaluation of the True Endpoint of Clinical Trials for Cancer Cachexia
por: Naito, Tateaki
Publicado: (2019)

Nursing Management of Cancer Cachexia: A New Frontier
por: Naito, Tateaki
Publicado: (2021)

Challenges in enhancing physical performance in thoracic cancer cachexia
por: Naito, Tateaki
Publicado: (2021)

Usefulness of the cachexia index as a prognostic indicator for patients with gastric cancer
por: Nakashima, Keigo, et al.
Publicado: (2023)

A protocol of a single arm, prospective, open-label, multicenter, phase II study of ramucirumab and erlotinib in treatment-naïve non-small cell lung cancer patients with EGFR mutation and brain metastases (SPIRAL-BRAIN study)
por: Sawada, Ryo, et al.
Publicado: (2023)

Efficacy of Anamorelin, a Novel Non-Peptide Ghrelin Analogue, in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) and Cachexia—Review and Expert Opinion
por: Currow, David C., et al.
Publicado: (2018)

The regulatory approval of anamorelin for treatment of cachexia in patients with non‐small cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer in Japan: facts and numbers.
por: Wakabayashi, Hidetaka, et al.
Publicado: (2020)

Ramucirumab Plus Docetaxel for Patients with Non-small cell Lung Cancer with Brain Metastases: A Multicenter, Open-Label Single-Arm Phase II Trial
por: Tanimura, Keiko, et al.
Publicado: (2023)

Impact of cancer cachexia on the therapeutic outcome of combined chemoimmunotherapy in patients with non-small cell lung cancer: a retrospective study
por: Morimoto, Kenji, et al.
Publicado: (2021)

Emerging Treatment Options For Cancer-Associated Cachexia: A Literature Review
por: Naito, Tateaki
Publicado: (2019)

Vascular endothelial growth factor promoter‐based conditionally replicative adenoviruses effectively suppress growth of malignant pleural mesothelioma
por: Harada, Akiko, et al.
Publicado: (2016)

Treatment rationale and design of the RAMNITA study: A phase II study of the efficacy of docetaxel + ramucirumab for non–small cell lung cancer with brain metastasis
por: Tanimura, Keiko, et al.
Publicado: (2018)

Advanced Non-Small-Cell Lung Cancer in Elderly Patients: Patient Features and Therapeutic Management
por: Takayuki, Nakano, et al.
Publicado: (2018)

Tumor Neovascularization and Developments in Therapeutics
por: Katayama, Yuki, et al.
Publicado: (2019)

Randomized Phase II Study of Weekly Paclitaxel plus Carboplatin Versus Biweekly Paclitaxel plus Carboplatin for Patients with Previously Untreated Advanced Non‐Small Cell Lung Cancer
por: Takayama, Koichi, et al.
Publicado: (2019)

Effects of the ghrelin receptor agonist anamorelin on lean body mass in cancer patients with cachexia; results from a Phase II randomized, double blind, multicenter study
por: Garcia, Jose M, et al.
Publicado: (2014)

The landscape of cancer cachexia in advanced non-small cell lung cancer: a narrative review
por: Morita-Tanaka, Satomi, et al.
Publicado: (2023)

Effects of the Cathepsin K Inhibitor ONO-5334 and Concomitant Use of ONO-5334 with Methotrexate on Collagen-Induced Arthritis in Cynomolgus Monkeys
por: Yamada, Hiroyuki, et al.
Publicado: (2019)

Appetite and food intake results from phase I studies of anamorelin
por: Blum, Robert A., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_or32h208jfklu0qohdh0qoddeo